DMXAA

Key Product Details

Product Description

DMXAA is a mSTING agonist; selective for mouse STING over human STING. Induces IFN-β and cytokine production from bone marrow-derived dendritic cells. Causes tumor regression following intratumoral administration in mouse tumor models. Induces an adaptive immune response to reduce systemic tumor growth and provides immunological memory against autologous tumor re-challenge. Also antiviral.

Product Specifications for DMXAA

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for DMXAA

The following data is based on the product molecular weight 282.29.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	17.71 mL	88.56 mL	177.12 mL
1 mM	3.54 mL	17.71 mL	35.42 mL
2 mM	1.77 mL	8.86 mL	17.71 mL
10 mM	0.35 mL	1.77 mL	3.54 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 15 publications citing the usage of this product.

• Corrales Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015 PMID: 25959818
• Phillips Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Biochem.Pharmacol. 1999 PMID: 10423172
• Shirey The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-β-mediated antiviral activity in vitro and in vivo. J.Leukoc.Biol. 2011 PMID: 21084628

Product Documents for DMXAA